How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Gram-Negative lnfections Market
- By Infection Type: Urinary Tract Infections (UTIs), Bloodstream Infections (BSIs), Respiratory Tract Infections, Intra-abdominal Infections, Skin and Soft Tissue Infections
- By Pathogen: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter species
- By Treatment Type: Antibiotics, Combination Therapy, Adjunctive Therapies, Supportive Care
- By Drug Class: Beta-lactams, Carbapenems, Aminoglycosides, Fluoroquinolones, Polymyxins
- By Patient Setting: Hospital-Acquired Infections (HAIs), Community-Acquired Infections (CAIs), Long-term Care Facilities
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urinary Tract Infections (UTIs) leads By Infection Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Gram-Negative lnfections Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Infection Type 5
Pathogen 5
Treatment Type 4
Drug Class 5
Patient Setting 3
Companies profiled
Pfizer Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc.
Roche Holding AG
Novartis AG
Sanofi S.A.
AstraZeneca plc
Bayer AG
AbbVie Inc.
Bristol-Myers Squibb Company
Gilead Sciences Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AstraZeneca plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Gilead Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Thermo Fisher Scientific Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Hoffmann-La Roche Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Fresenius SE & Co. KGaA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,121M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urinary Tract Infections (UTIs)52.9
- Bloodstream Infections (BSIs)15.6
- Respiratory Tract Infections13.6
- Intra-abdominal Infections6.7
- Skin and Soft Tissue Infections11.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$991.9M → $2,177M · 10.3%
Europe$691.3M → $1,758M · 12.4%
Asia Pacific$631.2M → $1,355M · 10.0%
Latin America$390.8M → $952.3M · 11.8%
Middle East and Africa$300.6M → $681.6M · 10.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.332026
11.352027
11.362028
11.372029
11.382030
11.402031
11.412032
11.412033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.22.1
- GlaxoSmithKline plc18.8
- Johnson & Johnson7.8
- Merck & Co. Inc.4.5
- Roche Holding AG10.3
- Novartis AG8.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Infection Type10.7%
Pathogen16.5%
Treatment Type25.8%
Drug Class21.6%
Patient Setting25.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.4
- Europe25.4
- Asia Pacific19.6
- Latin America13.8
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 75 | 74 | 89 | 86 | 83 | 80 | 81 |
| GlaxoSmithKline plc | 69 | 84 | 83 | 70 | 77 | 80 | 77 |
| Johnson & Johnson | 63 | 65 | 63 | 75 | 74 | 65 | 68 |
| Merck & Co. Inc. | 63 | 60 | 69 | 80 | 77 | 68 | 70 |
| Roche Holding AG | 58 | 65 | 56 | 62 | 77 | 75 | 66 |
| Novartis AG | 62 | 60 | 48 | 71 | 47 | 71 | 60 |
| Sanofi S.A. | 42 | 58 | 52 | 48 | 41 | 51 | 49 |
| AstraZeneca plc | 36 | 41 | 58 | 48 | 47 | 47 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| GlaxoSmithKline plc | − | ◐ | ✓ | ◐ | ◐ | ✓ |
| Johnson & Johnson | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Merck & Co. Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Roche Holding AG | − | ✓ | − | ✓ | ✓ | ✓ |
| Novartis AG | ◐ | ◐ | − | ✓ | − | ◐ |
| Sanofi S.A. | − | ◐ | − | − | − | ◐ |
| AstraZeneca plc | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.81
2GlaxoSmithKline plc77
3Merck & Co. Inc.70
4Johnson & Johnson68
5Roche Holding AG66
6Novartis AG60
7Sanofi S.A.49
8AstraZeneca plc46
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Pfizer Inc.
Challenger3
Strong scale, closing on the leaders.
GlaxoSmithKline plcJohnson & JohnsonMerck & Co. Inc.
Contender2
Focused players with pockets of strength.
Roche Holding AGNovartis AG
Niche2
Specialists in a single segment or region.
Sanofi S.A.AstraZeneca plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Infection Type in North America, then scale across Gram-Negative lnfections Market — a $291M beachhead inside a $5.11B market.
Beachhead (SOM)$291Mobtainable near-term
Serviceable (SAM)$2.04Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Urinary Tract Infections (UTIs)
Best fit — highest urgency & budget in Infection Type.
Economic buyer80 fit
Bloodstream Infections (BSIs)
Strong fit — clear ROI and a fast path to value.
End user70 fit
Respiratory Tract Infections
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Infection Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Pathogen & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Infection Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Gram-Negative lnfections Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified20%
Evaluation14%
Closed-won6%
$9.8KCAC
$54KLTV
5.5:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Gram-Negative lnfections Market is a resilient opportunity — $7.77B by 2033, compounding at 5.2%.
TAM · 2025$5.19Btoday
TAM · 2033$7.77Bforecast
CAGR5.2%2027–2033
Cumulative$57.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.77BTotal addressable market
SAM$2.71BServiceable available market
SOM$593MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.2% CAGR
Demand compounds through 2033, outpacing GDP across Infection Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Infection Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.77BLarge & growingTAM by 2033 at 5.2% CAGR
$2.71BServiceable nowreachable with today’s model
$593MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.06BBear3.4% CAGR
$7.77BBase5.2% CAGR
$9.94BBull6.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Pathogen optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Gram-Negative lnfections Market — a $5.49B market by 2033. Plan: grow share from 6.8% to 12.0%.
Market size · 2033$5.49Btotal addressable
Market CAGR4.3%2027–2033
Target share12.0%from 6.8% today
Revenue ambition$659Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 12.0% | At risk |
| Revenue | $407M | $659M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 29.6% | 44.8% | On track |
| Customer retention | 88.7% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Infection Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Pathogen capability
A defensible second engine — invest in Pathogen to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Infection Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Pathogen
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $79M capacity & capability investment
- Greenlight bolt-on M&A in Pathogen
- Authorise North America expansion plan
- Fund R&D program for Infection Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Gram-Negative lnfections Market conversation — a $7.48B market you can size, segment and defend in minutes.
Market size · 2033$7.48Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,671+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Infection Type
Goal Grow share in Infection Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$59K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Pfizer Inc.GlaxoSmithKline plcJohnson & JohnsonMerck & Co. Inc.Roche Holding AGNovartis AGSanofi S.A.AstraZeneca plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Gram-Negative lnfections Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Gram-Negative lnfections Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Gram Negative Identification Panel Market
Market size, share, segmentation and regional forecast.
$388M market · 2025 base year
View reportGramicidin Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportGraft Versus Host Disease Treatment Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportGraft Delivery Device Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportGraduated Pipette Market
Market size, share, segmentation and regional forecast.
$687M market · 2025 base year
View reportGraduated Elastic Compression Socks Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportGraduated Compression Socks Market
Market size, share, segmentation and regional forecast.
$982M market · 2025 base year
View reportGradient Thermal Cyclers Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportGradient Polymerase Chain Reaction Instrument Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportGradient PCR Machine Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportGradient PCR Instrument Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportGradient Medium for Sperm Separation Market
Market size, share, segmentation and regional forecast.
$501M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.